10-K: Kraig Biocraft Laboratories Reports Financial Results for Fiscal Year 2024, Outlines Strategic Initiatives

Kraig Biocraft Laboratories reports its financial results for the year ended December 31, 2024, highlighting ongoing efforts in recombinant spider silk production and strategic collaborations.

Summary

• Kraig Biocraft Laboratories, a Wyoming corporation, focuses on developing high-strength fibers using recombinant DNA technology for various commercial applications.
• The company uses genetically engineered silkworms to produce spider silk proteins, targeting markets like performance apparel, medical implants, and luxury fashion.
• Kraig Biocraft believes it is a world leader in commercially scalable and cost-effective spider silk fiber production.
• The company's primary technology involves natural and engineered variants of spider silk produced in domesticated mulberry silkworms.
• In January 2022, the company completed production of the first Dragon Silk yarn entirely in Vietnam.
• In 2024, the company made substantial progress in improving robustness of its laboratory strains.
• On January 24, 2024, the company signed a memorandum of understanding with the Vietnam Sericulture Association (VSA) and the Lam Dong Agro-Forestry Research & Experiment Center (LAREC) to enhance sericulture in Vietnam.
• On January 21, 2025, the company entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., allowing the company to sell up to $10 million of its shares of common stock.
• The company's net loss for the year ended December 31, 2024, was $3,398,939, and the accumulated deficit is $53,085,719.
• The company's independent auditor included an explanatory paragraph stating that the company's net loss from operations and net capital deficiency raise substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with a significant net loss and auditor's doubt about the company's ability to continue as a going concern. While there are some positive developments, the overall sentiment is negative due to the financial risks.

Positives

• The company completed production of the first Dragon Silk yarn entirely in Vietnam in January 2022.
• Substantial progress was made in 2024 to improve the robustness of laboratory strains.
• The company signed a memorandum of understanding with the Vietnam Sericulture Association (VSA) and the Lam Dong Agro-Forestry Research & Experiment Center (LAREC) to enhance sericulture in Vietnam.
• The company entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., allowing the company to sell up to $10 million of its shares of common stock.

Negatives

• The company's net loss for the year ended December 31, 2024, was $3,398,939, and the accumulated deficit is $53,085,719.
• The company's independent auditor included an explanatory paragraph stating that the company's net loss from operations and net capital deficiency raise substantial doubt about its ability to continue as a going concern.
• The company's disclosure controls and procedures are not effective as of December 31, 2024.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital and achieve sustainable revenues and profitable operations.
• The company's cash resources are insufficient to meet its planned business objectives without additional financing.
• There is no assurance that any future financing will be available or, if available, that it will be on terms that are satisfactory to the company.
• The company's internal control over financial reporting was not effective as of December 31, 2024, due to material weaknesses.

Future Outlook

The company plans to accelerate and expand commercial scale production of its recombinant spider silk, expand research and development, create a line of recombinant spider silk fashion wear, continue the expansion of overseas production operations, and actively pursue collaborative research and product testing opportunities.

Industry Context

The company operates in the technical textiles market, which was estimated at greater than $200 billion in 2024 and projected to reach $272 billion by 2030.

Comparison to Industry Standards

• The company competes with Bolt Threads, Inc., Spiber Inc., and AMSilk in the spider silk industry.
• These competitors have raised and spent 100s of millions of dollars in pursuit of spider silk production.
• Kraig Biocraft believes that its technology offers more cost-effective methods with lower environmental impact than technologies used by its identified competitors.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial condition and the potential for dilution through equity financing.
• Employees face uncertainty due to the company's financial condition and potential need for cost-cutting measures.
• Customers may be impacted by the company's ability to deliver on its product development and commercialization plans.
• Suppliers and creditors face risk due to the company's financial condition and potential inability to meet its obligations.

Next Steps

• The company plans to accelerate and expand commercial scale production of its recombinant spider silk.
• The company plans to expand its research and development to accelerate its work in creating next generation materials and to improve the robustness of its recombinant spider silk lines.
• The company plans to create a line of recombinant spider silk fashion wear either under its own brand name or in partnership with existing commercial entities.
• The company plans to continue the expansion of its overseas production operations, including working with local contractors or cooperatives and the hiring of additional direct staff, as needed.
• The company plans to accelerate its microbiology research and development to create more advanced materials.
• The company plans to develop more advanced spider silk and non-spider silk based fibers for select target markets.
• The company will consider buying an established revenue producing company in a compatible business, in order to broaden its financial base and facilitate the commercialization of its products.
• The company will also actively consider pursuing collaborative research opportunities with private laboratories in areas of research which overlap the company's existing research and development.
• The company plans to actively pursue collaborative research and product testing opportunities with companies in the biotechnology, materials, textile, and other industries.
• The company plans to actively pursue additional collaborative commercialization, marketing, and manufacturing opportunities with companies in the textile and material sectors for the fibers it developed and for any new polymers that it creates in 2025 and going forward.
• The company plans to actively pursue an uplist to a national exchange if such an opportunity presents itself.

Key Dates

Keywords

spider silk, recombinant DNA, silkworms, Dragon Silk, technical textiles, financial results, Kraig Biocraft Laboratories